Sun Pharma Targets $12 Billion Organon Acquisition to Bolster Global Specialty Portfolio
Strategic Expansion in the Pharmaceutical Sector Sun Pharmaceutical Industries, India’s largest drugmaker, is currently evaluating a complex financing structure for a proposed $12 billion acquisition of Organon, a move that signals a decisive shift toward expanding its global specialty drug footprint. The deal, which has dominated industry headlines this week, represents one of the most…